The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy

NCT04670107 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
Angiogenesis
Immunotherapy

Interventions

DRUG: Anlotinib in combination with Immune checkpoint inhibitors

Sponsor

The Affiliated Hospital of Qingdao University